We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




血液筛查试剂在中国和巴西获批

By LabMedica International staff writers
Posted on 23 Jan 2011
全球市场上筛查捐献血液中1型人类免疫缺陷病毒(HIV)和乙肝及丙肝病毒的一种试剂日前获准在中国和巴西使用。

这种高灵敏度、全集成、全自动化的Procleix Ultrio测定在TIGRIS平台上运行,它简化了工作流并提高了实验室的效率,这是确保检验和结果准时完成的关键因素。

在中国,诺华诊断公司(Basel, Switzerland; www.novartisdiagnostics.com)在2010年11月4-6日于成都举行的中国输血协会(CSBT)第五届输血大会上发布了Procleix Ultrio测定和Procleix TIGRIS平台;在巴西,诺华在2010年11月5-8日于巴西利亚举行的HEMO-巴西会议上展出了Procleix Ultrio测定和Procleix TIGRIS平台。

该公司正与中国和巴西的血液中心密切合作,推广Ultrio和TIGRIS并协助在血液筛查过程中再增加一道血液安全屏障。在中国,诺华诊断公司正与卫生部合作,推进2010中国核酸检测(NAT)试点项目,和血液中心分享Procleix Ultrio和TIGRIS系统的使用知识和最佳规范。
目前中国和巴西的血液筛查中心每年接受的献血分别为1000万人次和430万人次。两国的血液中心都在给血液筛查过程增加更多的安全保障,以提高从献血者到患者的链条上血液用品的安全性。

Related Links:
Novartis Diagnostics >> www.novartisdiagnostics.com
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
Online QC Software
Acusera 24•7
HPV Molecular Test
BD Onclarity HPV Assay
New
Automated Coagulation Analyzer
Hemolumi H6
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Graphical abstract (Pandya T, Zagorulya M, Leung MM, et al. Plasma signals of lung tumor promotion for molecular cancer prevention. Cell. 2026. doi:10.1016/j.cell.2026.05.005)

Plasma Protein Signature Predicts Lung Cancer Risk Up to Five Years Ahead

Lung cancer remains a leading cause of cancer death, and many cases are detected only after symptoms appear. Current screening programs largely target people with a history of smoking, leaving other at-risk... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.